EDA WHO Maturity Level 3: Scope Boundaries and Implications for Medical Devices

1. Key takeaways

The Egyptian Drug Authority (EDA) has attained World Health Organization Maturity Level 3 (ML3), but the boundary of that achievement must be stated precisely. According to the WHO list of national regulatory authorities operating at ML3 and ML4 (as of August 2026), the ML3 scope for the Egyptian EDA is 1. medicines 2. vaccines (production), with publication years of 2022 (vaccines) and 2024 (medicines). Medical devices are not within the ML3 scope. Egyptian official statements describe Egypt as the first African country to attain ML3 in both medicines and vaccines, and it is progressing toward ML3 reassessment and an ML4 target under the WHO routine reassessment procedure; the assessment uses the WHO Global Benchmarking Tool (GBT), with more than 260 indicators.

2. Legal basis

The maturity level claims trace to the WHO list, official Egyptian statements and the benchmarking instrument itself.

3. Expert insights

Insight 1: the scope of ML3 must always be stated: it is a medicines and vaccines achievement, not a device achievement.

In the WHO list, the scope of products column for Egypt contains only medicines and vaccines (production). By contrast, Singapore’s HSA (ML4) in the same list expressly includes medical devices as a numbered scope item. The conclusion is clear: device maturity is a separate assessment dimension. Describing the EDA’s ML3 as device regulation reaching ML3 is inaccurate.

Insight 2: that boundary explains exactly why Egypt is still legislating intensively on the device side.

In September 2025 five EDREX guidelines were revised together, in November 2025 the vigilance guideline was issued as a standalone document for the first time, and in May 2026 the UDI guideline moved to Version 02/2026. The common direction of these steps is bringing device regulation up to a level comparable with the medicines side. For companies, this means device-side rules are still in a period of rapid formation, and the cost of tracking them exceeds that on the medicines side.

Insight 3: reassessment and ML4 are official targets, and the assessment visit stage has begun.

According to the Egyptian Ministry of Health statement of July 15, 2025, the WHO delegation’s visit to Egypt was preparation for the 2026 ML3 reassessment, together with the necessary pre-assessment for reaching ML4 in vaccine and medicines finished dosage form manufacturing. When the EDA Chairman reported to the Prime Minister on September 13, 2026, he stated that Egypt is proceeding under the WHO routine reassessment procedure and has obtained WHO prequalification of its medicines quality control laboratory.

Insight 4: the scale of the GBT indicators shows how fine-grained the assessment is.

The Ministry of Health statement notes that the assessment is conducted by an international expert group led by the WHO using the WHO GBT, verifying regulatory performance across more than 260 indicators covering product licensing, product testing and market surveillance, among other functions, to determine the maturity level and institutional readiness. This granularity means the reassessment will touch many operational details, and the quality of company documentation will be indirectly scrutinised as well.

Insight 5: for device companies, the practical value of ML3 is indirect and reputational rather than procedural.

Because devices are outside the ML3 scope, ML3 cannot deliver simplification or mutual recognition for device registration. Its real significance lies elsewhere: first, it shows that the EDA’s overall governance capability has international recognition, making review outcomes more predictable; second, it shows the EDA has the incentive to complete the device side, so rules will keep densifying; third, for companies using Egypt as a regional manufacturing base, the medicines-side ML3 and laboratory WHO prequalification improve the overall business environment.

Insight 6: the comparison with other authorities in the same list is a useful communication anchor.

In the same WHO list, the NMPA of China holds ML3 with a scope of vaccines (production), published in 2022; South Africa’s SAHPRA holds ML3 for vaccines (production), published in 2022 and 2026; and Ethiopia’s EFDA holds ML3 for medicines, vaccines (non-production), published in 2025. Companies communicating across multiple markets can use this single list as a common reference to avoid inconsistent claims.

Insight 7: tracking should focus on the EDA website announcement section, not on news retellings.

ML3, ML4 and reassessment progress are published by the EDA and the WHO, and secondary reporting frequently misstates scope or years, for example writing medicines ML3 as device ML3. When citing maturity levels in external materials and tender documents, companies should check the original WHO list and state the scope and publication year alongside the level.

4. Practical recommendations

The following practices keep maturity claims accurate and useful.

1. Always state the scope when citing ML3: medicines and vaccines, not medical devices.
2. Never use ML3 to claim simplification or mutual recognition for device registration.
3. Build continuous device-side rule densification into the compliance budget: guideline revisions occur more frequently than on the medicines side.
4. Track the EDA website announcement section and updates to the WHO list, disregarding secondary retellings.
5. Watch the 2026 ML3 reassessment and ML4 progress: device-side evaluation may follow on the agenda.
6. Use the same WHO list as the reference in multi-market materials to keep claims consistent.
7. Use the EDA’s WHO-prequalified laboratories to assess local testing resource availability.

5. Verification checklist

• □ ML3 citations specify the scope as medicines and vaccines
• □ It is confirmed that ML3 is not used to claim device registration simplification or mutual recognition
• □ The WHO list version (August 2026) has been checked against the original
• □ The 2025-09 guideline revisions and the 2025-11 vigilance guideline are within the tracking scope
• □ The 2026-05 UDI guideline (GL.CAMD.005 02/2026) has been assessed
• □ ML3 reassessment and ML4 progress are set as periodic tracking items
• □ Maturity level claims in multi-market materials are aligned

Regulatory information verified as of October 29, 2026. The maturity level and scope information in this article follows the World Health Organization List of NRAs operating at ML3 and ML4 (version as of August 2026); reassessment and ML4 targets follow the official public statements of the Egyptian Ministry of Health and the EDA.

• Egypt local support: GRZAN assists manufacturers from the Chinese mainland and overseas with EDA medical device registration, import approval and variation applications, including registration applicant pathway design (importing company, local factory, or Scientific Office), preparation for Scientific Committee evaluation, demonstration of free sale certificate routes from reference countries, Arabic labelling and instructions-for-use localization, and the setup of vigilance and periodic reporting systems.
• Service capabilities: product classification and risk grading (devices Class I–III, IVD Class A–D), registration and re-registration, applicability assessment for system registration and bundled registration, three-way variation classification, import approval and annual import plans, and support for vigilance reporting and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.